Liminatus Pharma (LIMN) has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework. This internal review is part of Liminatus’s continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments-including blockchain-based assets-that may enhance treasury efficiency and diversify non-operating capital reserves.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIMN: